Defence Therapeutics Statistics

Total Valuation

Defence Therapeutics has a market cap or net worth of CAD 23.68 million. The enterprise value is 25.37 million.

Market Cap	23.68M
Enterprise Value	25.37M

Important Dates

The next estimated earnings date is Thursday, October 24, 2024.

Earnings Date	Oct 24, 2024
Ex-Dividend Date	n/a

Share Statistics

Defence Therapeutics has 45.54 million shares outstanding. The number of shares has increased by 12.54% in one year.

Shares Outstanding	45.54M
Shares Change (YoY)	+12.54%
Shares Change (QoQ)	+2.00%
Owned by Insiders (%)	5.55%
Owned by Institutions (%)	n/a
Float	43.01M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.92
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-5.65

Financial Position

The company has a current ratio of 0.05

Current Ratio	0.05
Quick Ratio	0.04
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.39
Interest Coverage	-32.04

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-397.30%
Return on Capital (ROIC)	-1,080.63%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -76.79% in the last 52 weeks. The beta is 1.48, so Defence Therapeutics's price volatility has been higher than the market average.

Beta (5Y)	1.48
52-Week Price Change	-76.79%
50-Day Moving Average	0.67
200-Day Moving Average	1.37
Relative Strength Index (RSI)	38.98
Average Volume (20 Days)	29,651

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-12.75M
Pretax Income	-13.19M
Net Income	-13.19M
EBITDA	-12.68M
EBIT	-12.75M
Earnings Per Share (EPS)	-0.30

Full Income Statement

Balance Sheet

The company has 56,547 in cash and 1.75 million in debt, giving a net cash position of -1.69 million or -0.04 per share.

Cash & Cash Equivalents	56,547
Total Debt	1.75M
Net Cash	-1.69M
Net Cash Per Share	-0.04
Equity (Book Value)	-3.58M
Book Value Per Share	-0.08
Working Capital	-3.84M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.29 million and capital expenditures -203,239, giving a free cash flow of -4.49 million.

Operating Cash Flow	-4.29M
Capital Expenditures	-203,239
Free Cash Flow	-4.49M
FCF Per Share	-0.10

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Defence Therapeutics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-12.54%
Shareholder Yield	-12.54%
Earnings Yield	-56.84%
FCF Yield	-18.97%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a